C4 Therapeutics, Inc.

Cemsidomide is advancing through Phase 2 MOMENTUM and Phase 1b combination studies, with key data catalysts expected at EHA 2026 and throughout 2026–2027. Validation from Bristol-Myers' Phase 3 mezigdomide data reinforces the strategic value of IKZF1/3 degraders and supports CCCC's best-in-class ambitions in relapsed/refractory multiple myeloma.

Despite early promise, cemsidomide faces significant safety concerns and long timelines before definitive data readouts are available. The early-stage nature of the data and absence of near-term catalysts make it difficult to justify a strong conviction position, warranting a cautious stance on the program's ultimate clinical and commercial success.

With $268.3M in cash as of March 2026, C4 Therapeutics has a strong financial position that supports operations into 2028. This extended runway reduces near-term dilution risk and provides sufficient capital for continued pipeline expansion, clinical execution, and exploration of combination study opportunities.

While cash reserves reduce immediate financing pressure, the company's high cash burn rate remains a core concern. Analysts note the company is forecast to remain unprofitable over the next three years, with a future return on equity of just 0.47%, raising questions about long-term capital efficiency and the need for future dilutive financing.

Following a significant market valuation decline, CCCC's stock price has re-aligned more closely with its early-stage clinical status, reducing overvaluation risk. Analysts at Stifel upgraded the stock to Buy with a price target raise, and revenue is forecast to grow at 78.4% per year — far outpacing the broader US market growth of 13% per year.

Some analysts maintain that the company's current valuation remains high compared to sector peers given its unprofitable outlook over the next three years. With low analyst coverage, limited near-term revenue catalysts, and a hold rating from multiple analysts, the risk/reward profile does not yet justify a more aggressive position.